C4 Therapeutics (CCCC) Operating Expenses (2019 - 2026)

C4 Therapeutics' Operating Expenses history runs 8 years deep, the most recent figure standing at $33.9 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 6.77% year-over-year to $33.9 million; the TTM figure through Mar 2026 stood at $148.7 million (down 4.89% YoY), while the FY2025 annual figure was $151.2 million, down 2.6% from the prior year.
• Operating Expenses was $33.9 million for Q1 2026 at C4 Therapeutics, down from $34.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $45.6 million in Q3 2025 to a low of $33.4 million in Q2 2024.
• Historically, Operating Expenses has averaged $38.9 million across 5 years, with a median of $39.2 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses jumped 39.69% in 2022, then declined 20.34% in 2025.
• A 5-year view of Operating Expenses shows it stood at $41.1 million in 2022, then slipped by 1.12% to $40.7 million in 2023, then climbed by 5.4% to $42.9 million in 2024, then decreased by 20.34% to $34.2 million in 2025, then decreased by 0.66% to $33.9 million in 2026.
• The last three Operating Expenses figures came in at $33.9 million (Q1 2026), $34.2 million (Q4 2025), and $45.6 million (Q3 2025), per Business Quant data.